An overview of pancreatic cancer diagnosis and treatment in China: Current landscape and future prospects.

Abstract

This comprehensive literature review is to summarize the most recent findings regarding the causes,
diagnosis, and treatments of pancreatic cancer and to encourage additional investigation into this under
researched malignant tumor. Pancreatic cancer is a significant public health issue in China, with annual
mortality rates almost equal to incidence rates. The disease is more prevalent in rural areas and has a poor
prognosis. The data was collected from the following databases: Pub Med, Cross ref, Science Direct,
Scopus, and Google Scholar we reviewed published articles from 2018 to 2023 on the annual incidence
of pancreatic cancer in China is 5.1%, with only 5-7% of patients completely cured. The prognosis is
extremely poor, with a 1-year survival rate of 8% and a 5-year survival rate of 3%. Pancreatic cancer has
no specific clinical manifestations or tumor markers, and its characteristics are not typical of high-risk
factors including smoking, alcohol, chronic pancreatitis, abnormal microorganism metabolism, blood
type, and glucose and lipid levels. For increased detection and survival rates, pancreatic cancer must be
diagnosed as early as possible. However, the low specificity of tumor markers calls for more study.
Future treatment strategies could include immunotherapy and a microbiology-free system, and it's
anticipated that they'll offer intriguing clinical applications for extending patients' lives with pancreatic
cancer. Finally, we suggest measures to improve the health outcomes of pancreatic cancer patients in
China.